Atossa Therapeutics (NASDAQ:ATOS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $4.00 price objective on the stock.

A number of other analysts have also recently commented on the company. Cantor Fitzgerald restated an overweight rating on shares of Atossa Therapeutics in a research report on Friday, January 12th. StockNews.com cut shares of Atossa Therapeutics from a hold rating to a sell rating in a research note on Monday, March 18th.

Atossa Therapeutics Price Performance

ATOS opened at $1.54 on Tuesday. The firm has a fifty day moving average price of $1.37 and a 200 day moving average price of $0.98. Atossa Therapeutics has a 1 year low of $0.59 and a 1 year high of $2.31. The stock has a market cap of $192.96 million, a P/E ratio of -6.42 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOS) last posted its earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. Equities analysts expect that Atossa Therapeutics will post -0.28 EPS for the current year.

Insider Activity at Atossa Therapeutics

In other news, Director Jonathan Finn acquired 25,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were bought at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the acquisition, the director now owns 25,000 shares in the company, valued at approximately $44,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATOS. UBS Group AG purchased a new stake in Atossa Therapeutics in the 3rd quarter valued at $25,000. First Republic Investment Management Inc. increased its holdings in Atossa Therapeutics by 79.8% in the first quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock valued at $31,000 after buying an additional 11,167 shares during the last quarter. Two Sigma Securities LLC acquired a new position in shares of Atossa Therapeutics in the 2nd quarter valued at $32,000. XTX Topco Ltd purchased a new stake in Atossa Therapeutics during the 2nd quarter valued at approximately $50,000. Finally, LPL Financial LLC acquired a new stake in Atossa Therapeutics during the 2nd quarter worth approximately $59,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.